CD269/TNFRSF17/BCMA Human Monoclonal Antibody
Anti-Human CD269/TNFRSF17/BCMA (BUIPXDEOC) is a research-grade recombinant antibody targeting CD269. Produced in mammalian cells with native-like glycosylation. Highlights Research Grade: For PK/PD studies, assay development, and ADA research. Native Glycosylation: Mammalian expression ensures native-like patterns.
Product Specifications
Product Name Alternative
Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM
UniProt
Q02223
Reactivity
Human
Clonality
Monoclonal
Clone
BUIPXDEOC
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation
Purification
Protein A/G purified from cell culture supernatant.
Concentration
Lot dependent
Purity
>95% purity as determined by SDS-PAGE.
Form
Liquid
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Tested Applications
ELISA, FA, FACS, In vivo
Host or Source
Human
Preservative
0.01M PBS, pH 7.4.
Isotype
IgG
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD59 (heavy chain of Protectin) (BRA-10G), CF568 conjugate, 0.1mg/mL
CD35 / CR1 (E11), CF568 conjugate, 0.1mg/mL
HER-2 / CD340 (HRB2/718), CF568 conjugate, 0.1mg/mL
Neurofilament (NF-L) (NFL/736), CF640R conjugate, 0.1mg/mL
